Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pregnancy Clear all
Not yet recruiting Phase 2 Interventional

A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

NCT07773727
View directory record Official record
Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
ARGX-121, Placebo
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Miami, Florida • Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed No phase listed Observational

Chitosan Chewing Gum Study in Dialysis Patients

NCT01770470
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Chitosan
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 3 Interventional

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

NCT05299554
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort
Drug
Lead sponsor
Immedica Pharma AB
Industry
Eligibility
16 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Healthy Mom Zone Gestational Weight Gain Management Intervention 2.0

NCT05807594
View directory record Official record
Conditions
Gestational Weight Gain, Overweight and Obesity, Pregnancy, Energy Balance
Interventions
HMZ 2.0 Intervention, Attention Control Intervention
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Role of Mobile Apps in Promoting Cardiovascular Health and Motivation to Exercise During Pregnancy

NCT07166822
View directory record Official record
Conditions
Cardiovascular (CV) Risk, Exercise
Interventions
Experimental group using BumptUp mobile exercise app
Behavioral
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Asdzáán Be'eená Teen Pregnancy and Substance Use Prevention Program for Native American Youth and Their Caregiver

NCT04863729
View directory record Official record
Conditions
Sex Behavior
Interventions
Asdzaan Be'eena Program
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
10 Years to 14 Years · Female only
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Chinle, Arizona • Tuba City, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

NCT01693029
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease (CKD)
Interventions
HX575 epoetin alfa, US-licensed epoetin alfa
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
52
States / cities
Tempe, Arizona • Azusa, California • Bakersfield, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

NCT04935294
View directory record Official record
Conditions
Healthy, Renal Dysfunction
Interventions
Danicopan
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

NCT02166905
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Epacadostat, Laboratory Biomarker Analysis, Pharmacological Study, Poly ICLC
Biological · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 19, 2026, 8:02 AM EDT
Recruiting Phase 2 Interventional

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

NCT07516366
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Balstilimab, Biospecimen Collection, Botensilimab, Computed Tomography, Nephrectomy, Questionnaire Administration
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD

NCT06343129
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Dietary education program
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 19, 2026, 8:02 AM EDT
Recruiting Not applicable Interventional

Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)

NCT05849077
View directory record Official record
Conditions
Premature Infants, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Neurodevelopmental Outcomes
Interventions
Sat75, Sat50
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Minutes to 10 Minutes
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

NCT03300557
View directory record Official record
Conditions
Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Accuracy and Reliability of Fetal Heart Rate and Uterine Contraction Monitoring Method

NCT01280357
View directory record Official record
Conditions
Pregnancy; Habitual Aborter, Weeks of Gestation 37 or More
Interventions
Monica AN24 (K101081), Philips 50XM
Device
Lead sponsor
Monica Healthcare Ltd
Industry
Eligibility
15 Years to 40 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

The Measurement of Insulin Resistance in Peritoneal Dialysis Patients

NCT01119196
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Icodextrin dialysate
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Sep 19, 2026, 8:02 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

NCT06353269
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Hypoestrogenism
Interventions
Estring Vaginal Product, Vagifem, Estrace 0.01% Vaginal Cream
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

An Analgesia Protocol for Acute Renal Colic in the Emergency Department

NCT00504283
View directory record Official record
Conditions
Kidney Stone
Interventions
Toradol, Morphine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 17, 2007 · Synced Sep 19, 2026, 8:02 AM EDT
Terminated Phase 3 Interventional Results available

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

NCT02377466
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban IV infusion, Placebo IV infusion
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

NCT02449902
View directory record Official record
Conditions
Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions
Estradiol, placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

Transverse Abdominis Plane (TAP) Block After Cesarean Delivery

NCT01170702
View directory record Official record
Conditions
Postoperative Pain, Pregnancy, Obesity
Interventions
0.9% Normal Saline, 0.2% Ropivacaine, 0.5% Ropivacaine, 0.75% Ropivacaine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 19, 2026, 8:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

NCT05126472
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
anti-CD40 antibody 2141-V11, Intravesical Gemcitabine, Intravesical Gemcitabine with anti-CD40 antibody 2141-V11
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria

NCT00493727
View directory record Official record
Conditions
Diabetes, Proteinuria
Interventions
N-acetylcysteine(Mucomyst)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2008 · Synced Sep 19, 2026, 8:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Lung Structure and Function of Infants Born Prematurely

NCT00422305
View directory record Official record
Conditions
Premature Birth, Bronchopulmonary Dysplasia, Asthma
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 36 Months
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 19, 2026, 8:02 AM EDT